TrivarX Valuation

Is TRI undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of TRI when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate TRI's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate TRI's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for TRI?

Key metric: As TRI is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for TRI. This is calculated by dividing TRI's market cap by their current revenue.
What is TRI's PS Ratio?
PS Ratio	8.2x
Sales	AU$888.83k
Market Cap	AU$7.31m

TRI key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	7.3x
Enterprise Value/EBITDA	-4.9x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does TRI's PS Ratio compare to its peers?

The above table shows the PS ratio for TRI vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	13.8x
ICR Intelicare Holdings	18.9x	n/a	AU$5.4m
GLH Global Health	0.9x	n/a	AU$8.0m
TD1 TALi Digital	33.8x	n/a	AU$4.9m
VFX Visionflex Group	1.7x	n/a	AU$11.7m
TRI TrivarX	8.2x	n/a	AU$7.3m

Price-To-Sales vs Peers: TRI is good value based on its Price-To-Sales Ratio (8.2x) compared to the peer average (13.8x).

Price to Sales Ratio vs Industry

How does TRI's PS Ratio compare vs other companies in the AU Healthcare Services Industry?

7 Companies	Price / Sales	Estimated Growth	Market Cap
MDR MedAdvisor	1.3x	13.4%	US$103.96m
DOC Doctor Care Anywhere Group	0.3x	6.3%	US$15.26m
IME ImExHS	0.7x	20.5%	US$11.85m
VFX Visionflex Group	1.7x	n/a	US$7.59m

7 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Sales vs Industry: TRI is expensive based on its Price-To-Sales Ratio (8.2x) compared to the Global Healthcare Services industry average (2.9x).

Price to Sales Ratio vs Fair Ratio

What is TRI's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

TRI PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	8.2x
Fair PS Ratio	n/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate TRI's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Doctor Care Anywhere Group

AU$23.5m

Provides digital healthcare and development services in the United Kingdom, Australia, and the Republic of Ireland.

DOC

AU$0.064

-4.5%

33.3%

Cogstate

AU$166.4m

A neuroscience technology company, engages in the creation, validation, and commercialization of digital brain health assessments used in both academic and industry sponsored research.

CGS

AU$0.96

-2.5%

-36.9%

CardieX

AU$30.9m

Engages in the design, manufacture, and marketing of medical devices used in cardiovascular health management in the Americas, Europe, and the Asia Pacific.

CDX

AU$0.10

-22.2%

n/a